Steve Pontell – Newest Board Member
The Life Raft Group announces Steve Pontell, Esq. as the newest addition to our Board of Directors.
Patient Advocate’s Story Unfolds in RARE Revolution Magazine
Deb Melikian, patient advocate, and Dr. Jason Sicklick, GIST expert & researcher, share the story of their unique partnership which began at an LRG GIST Day of Learning in the rare partners issue of RARE Revolution Magazine.
New GIST Treatments by Prof. Merimsky
New GIST Treatments by Prof. Merimsky
Case Panel with Prof. Merimsky, Prof. Klausner and Dr. Shamai
Case analysis in GIST during a seminar for GIST Patients at Tel Aviv Medical Center (Ichilov).
Breaking News for GIST Patients – Avapritinib Approved!
Blueprint Medicines announced that the FDA has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
CTOS 2019 Highlights
CTOS, "The Connective Tissue Oncology Society", is an organization of medical specialists and researchers who specialize in bone and soft tissue tumors. They hold a meeting every year to discuss the latest innovations in this area. This year the meeting took place in Tokyo from November 13 until 16.
GIST Support UK & PAWS-GIST News!
The UK National Cancer Research Institute’s (NCRI) annual conference was held on November 3rd-5th. This year the conference was held in Glasgow (Scotland).
NDA for Ripretinib Submitted to FDA for Treatment of GIST
Breaking news in Targeted Oncology online today - A New Drug Application (NDA) for Ripretinib (DCC-2618) was submitted to FDA for treatment of GIST, by Deciphera.
First-Line Imatinib More Effective Than Widely Believed – LRG Science
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
Medicamentos Para GIST: Existentes y Nuevos
Esta presentación cuenta la historia de los medicamentos para GIST, de cómo llagamos a donde hoy estamos, y como miramos hacia donde vamos en el futuro. Entrega información de cada medicamento que ha sido [...]